AstraZeneca's Latest FDA Approval Provides Hope For Pancreatic Cancer Patients

|
About: AstraZeneca PLC (AZN), Includes: MRK, MYGN
by: Terry Chrisomalis
This article is exclusive for subscribers.
Terry Chrisomalis
Long only, biotech, healthcare, short only
Summary

AstraZeneca and its partner Merck received FDA approval for Lynparza for 1st line maintenance treatment for metastatic pancreatic cancer patients with the BRCA mutation.

Lynparza was able to reduce the risk of disease progression or death by 47% when given to these metastatic pancreatic cancer patients with BRCA mutation.

In order to determine patients that will respond to Lynparza they undergo Myriad Genetics BRACAnalysis CDx diagnostic, which detects if patients have germline variants of BRCA1 and BRCA2.

Lynparza sales continue to climb, reaching $327 million in Q3 of 2019 alone.

AstraZeneca (AZN) and its partner Merck & Co. (MRK) announced that Lynparza was approved by the FDA as a maintenance treatment for metastatic pancreatic cancer patients with the BRCA mutation. This